Abstract: According to various aspects of the present disclosure, an apparatus is provided. In an aspect, the apparatus includes an optical transceiver having a first port, a second port and an optical switch coupled to the first port and the second port. The optical switch is switchable between a unidirectional port operation mode and a bidirectional port operation mode. When the optical switch is in the unidirectional port operation mode, the first port is configured to send a first optical signal, and the second port configured to receive a second optical signal. When the optical switch is in the bidirectional port operation mode, the first port configured to send the first optical signal and receive the second optical signal, and the second port configured to receive a third optical signal and not send the first signal.

Abstract: An apparatus includes a tail-end optical switch configured to be coupled to a broadcast star network that couples the tail-end optical switch to a head-end optical switch by a primary bidirectional optical path and a second bidirectional optical path. The tail-end optical switch having a first optical switch and a second optical switch configured to provide active switching.

Abstract: Systems, methods and cartridges for carbonating or otherwise dissolving gas in a precursor liquid, such as water, to form a beverage. A gas source can be provided in a cartridge which is used to generate gas that is dissolved into the precursor liquid. A beverage medium, such as a powdered drink mix or liquid syrup, may be provided in the same, or a separate cartridge as the gas source and mixed with the precursor liquid to form a beverage. The use of one or more cartridges for the gas source and/or beverage medium may make for an easy to use and mess-free system for making sparkling beverages, e.g., in the consumer's home.

Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Abstract: An apparatus includes a first input port, a first switch, and a second switch. The first switch and the second input port are in optical communication with the first input port. The apparatus also includes a second input port, a third switch, and a fourth switch. The third switch and the fourth switch are in optical communication with the second input port. Each switch is switchable between a first state to pass optical signals and a second state to block optical signals. The apparatus also includes a first combiner in optical communication with the first input port via the first switch and the second input port via the third switch. The apparatus also includes a second combiner in optical communication with the first input port via the second switch and the second input port via the fourth switch.

Abstract: A method for the prediction, prognosis and/or diagnosis of bladder cancer or bladder cancer recurrence in a subject, the method includes: providing a test sample from the subject; measuring DNA methylation levels of at least a portion of two or more polynucleotides selected from the group consisting of HOXA9, SOX1, NPY, IRAK3, L1-MET, and ZO2 in the test sample; calculating a risk score based on the measured DNA methylation levels, comparing the calculated risk score to a cut-off value derived from a reference DNA methylation profile based on DNA methylation levels of the one or more biomarkers derived from a control group, members of which had bladder cancer; and based on the comparison calculated risk score to the cut-off value, determining at least one of: (1) whether bladder cancer has recurred; (2) whether there is likelihood that the bladder cancer will recur; and (3) whether the patient has bladder cancer. The one or more polynucleotides preferably comprise SOX1, IRAK3 and L1-MET.

Abstract: The present invention relates to a device for the examination of neurons and to a method for examining neurons, and more specifically for examining neurons growing in a three-dimensional network.

Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: An apparatus includes a first input port, a first switch, and a second switch. The first switch and the second input port are in optical communication with the first input port. The apparatus also includes a second input port, a third switch, and a fourth switch. The third switch and the fourth switch are in optical communication with the second input port. Each switch is switchable between a first state to pass optical signals and a second state to block optical signals. The apparatus also includes a first combiner in optical communication with the first input port via the first switch and the second input port via the third switch. The apparatus also includes a second combiner in optical communication with the first input port via the second switch and the second input port via the fourth switch.

Abstract: A cylinder head defines an EGR crossover tube integrally formed in the cylinder head. The EGR crossover tube includes a first end fluidly coupled to an exhaust port of an engine. A second end is fluidly coupled to an intake port of the engine. A Venturi tube configuration is positioned between the first and second ends. A first sensor port extends through the cylinder head to the EGR crossover tube. The first sensor port is positioned at a restriction of the Venturi tube configuration. A second sensor port extends through the cylinder head to the EGR crossover tube. The second sensor port is positioned proximate the first end. A differential pressure sensor includes a first pressure sensor positioned in the first sensor port and a second pressure sensor positioned in the second sensor port.

Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: Provided is an abatement device that reduces an amount of drainage of circulating water. The abatement device lowers an average drainage flow of circulating water to a low flow, when a ratio of a concentration of silicon dioxide within the circulating water and a concentration of hydrogen fluoride within the circulating water is greater than or equal to a predetermined value at which hydrofluorosilicic acid can be produced, and raises the average drainage flow of the circulating water to a high flow higher than the low flow, when the ratio of the concentration of silicon dioxide within the circulating water and the concentration of hydrogen fluoride within the circulating water is less than the predetermined value.

Abstract: The present invention relates to boron containing compounds of Formula (I) X—Y—Z?? Formula (I) that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

Abstract: An apparatus includes a first reconfigurable optical add/drop multiplexer (ROADM) to receive a first optical signal and a second ROADM to receive a second optical signal. The apparatus also includes a reconfigurable optical switch that includes a first switch, switchable between a first state and a second state, to transmit the first optical signal at the first state and block the first optical signal at the second state. The reconfigurable optical switch also includes a second switch, switchable between the first state and the second state, to transmit the second optical signal at the first state and block the second optical signal at the second state. The reconfigurable optical switch also includes an output port to transmit an output signal that is a sum of possible optical signals transmitted through the first switch and the second switch.

Abstract: A method for the prediction, prognosis and/or diagnosis of bladder cancer or bladder cancer recurrence in a subject, the method includes: providing a test sample from the subject; measuring DNA methylation levels of at least a portion of two or more polynucleotides selected from the group consisting of HOXA9, SOXI, NPY, IRAK3, L1-MET, and Z02 in the test sample; calculating a risk score based on the measured DNA methylation levels, comparing the calculated risk score to a cut-off value derived from a reference DNA methylation profile based on DNA methylation levels of the one or more biomarkers derived from a control group, members of which had bladder cancer; and based on the comparison calculated risk score to the cut-off value, determining at least one of: (1) whether bladder cancer has recurred; (2) whether there is likelihood that the bladder cancer will recur; and (3) whether the patient has bladder cancer.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: A distributed file storage services (DFSS) that provides low latency (LL) and high throughput (HT) modes for file systems. A HT metadata subsystem (HTMS) may use a distributed transaction system for data and metadata reads and writes for file systems in HT mode. A LL metadata subsystem (LLMS) may process metadata requests for file systems in LL mode. For metadata read requests, the LLMS may locally cache at least some of the file system metadata. For metadata write requests, the LLMS may write entries to a journal and notify the access node after the entries are committed to the journal. Data reads and writes for file systems in LL mode may be handled similarly to data reads and writes for file systems in HT mode. A file system may be converted from LL to HT mode, or from HT to LL mode.

Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.